Lishan Aklog's Insider Trades & SAST Disclosures
Lishan Aklog's most recent trade in Lucid Diagnostics Inc was a trade of 300,000 Common Stock done . Disclosure was reported to the exchange on Feb. 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lishan Aklog.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lucid Diagnostics Inc | Lishan Aklog | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 300,000 | 1,466,627 | - | 0 | Common Stock | |
| Lucid Diagnostics Inc | Lishan Aklog | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 400,000 | 1,166,627 | - | 0 | Common stock | |
| ContraFect Corp | Lishan Aklog | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 42,000 | 42,000 | - | - | Options (Right to Buy) | |
| PAVmed Inc | Lishan Aklog | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 28 Mar 2022 | 79,636 | 176,277 (0%) | 0% | 1.2 | 93,970 | Common stock |
| PAVmed Inc | Lishan Aklog | Director, Chairman and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 200,000 | 200,000 | - | - | Employee stock option (right to buy) | |
| Lucid Diagnostics Inc | Lishan Aklog | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 75,000 | 75,000 | - | - | Employee stock option (right to buy) | |
| Lucid Diagnostics Inc | Lishan Aklog | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 60,000 | 624,400 | - | 0 | Common stock | |
| ContraFect Corp | Lishan Aklog | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 25,000 | 25,000 | - | - | Options (Right to Buy) | |
| PAVmed Inc | Lishan Aklog | Director, Chairman and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 150,000 | 1,255,913 (3%) | 0% | 0 | Common Stock | |
| PAVmed Inc | Lishan Aklog | Director, Chairman and CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.31 per share. | 18 Mar 2021 | 7,500 | 1,105,913 (2%) | 0% | 4.3 | 32,324 | Common Stock |
| ContraFect Corp | Lishan Aklog | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2020 | 16,000 | 16,000 | - | - | Options (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges